Comparison of fixed combinations of dorzolamide/timolol and brimonidine/timolol in patients with primary open-angle glaucoma

Abstract

To compare the short-term effectiveness and ocular side-effects of fixed combinations of dorzolamide/timolol (DTFC) and brimonidine/timolol (BTFC) in patients with primary open-angle glaucoma (POAG). Forty-two eyes of 42 patients newly diagnosed with primary open-angle glaucoma were assessed prospectively. One of the two eyes was chosen randomly and treated with DTFC (2 × 1) for 4 weeks. The treatment was then stopped to allow a 4-week wash-out period. Following the wash-out period, the same eye was treated with BTFC (2 × 1) for 4 weeks. Intraocular pressure (IOP) values were measured before and after each treatment at 0800, 1,200 and 1,600 h. Tear function test results and ocular side-effects were also recorded. The mean baseline IOP values for DTFC and BTFC were 24.1 ± 1.8 and 24.6 ± 2.4 mmHg, respectively. The mean IOP values after 4 weeks of treatment with DTFC or BTFC were 17.1 ± 2.9 and 16.9 ± 2.5 mmHg, respectively. Both medications reduced IOP values significantly (P = 0.0000). The effectiveness of both medications was similar (P = 0.7363). Both combinations significantly reduced the amount of tear secretion and tear break-up time (P = 0.0000). Eye burning was more common with DTFC than with BTFC (P = 0.0182). Other adverse effects were observed at similar rates for both combinations. This study demonstrated that the IOP-reducing effects of DTFC and BTFC in patients with POAG are similar. The side-effect profile of BTFC is similar to that of DTFC. Lower occurrence of a burning sensation may improve patient compliance in the BTFC group.

Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension

“…Fixed-combination therapies enable instillation of multiple agents from one bottle, providing additive effects on IOP reduction compared with single agents and simplifying administration compared with multiple medications 15,16. Whereas several studies of short-term (up to one month) safety and efficacy of BRINZ/TIM-FC have been reported,35–37 long-term (≥12 months) clinical studies of BRINZ/TIM-FC ocular hypotensive therapy are limited 17. The goal of the current study was to evaluate the long-term safety and efficacy of BRINZ/TIM-FC in Japanese patients with open-angle glaucoma (primary open-angle, normal-tension, exfoliation, or pigmentary) or ocular hypertension.…”

Dorzolamide/Timolol-Fixed Combination For Primary Open-Angle Glaucoma: A Protocol For Systematic Review

“…At present, DTFC is the rst xed combination that comprises of dorzolamide and timolol, and is currently routinely utilized in clinical practice in treating POAG. To date, several clinical trials have investigated the e cacy and safety of DTFC for the treatment of POAG, and their ndings indicate that DTFC can signi cantly reduce IOP in patients with POAG [23][24][25][26][27][28][29][30][31]. To the best of our knowledge, rarely data at systematic level is available on assessing e cacy and safety of DTFC for the treatment of POAG.…”

“…DTFC exerts better e cacy than any single medication. Studies suggested that DTFC could help decrease IOP signi cantly in patients with POAG [23][24][25][26][27][28][29][30][31]. However, no systematic review has investigated the e cacy and safety of DTFC in treating POAG.…”

Dorzolamide Chlorhydrate versus Acetazolamide in the Management of Chronic Macular Edema in Patients with Retinitis Pigmentosa: Description of Three Case Reports

“…The main indications for the topical administration of dorzolamide are imbalanced trabecular blockage glaucoma (in combination with beta-blockers), and all those cases in which beta-blocker therapy is contraindicated. 16,17…”